Oct
2026
Fiera Milano, Italy
Visit us
stand 12C57, Contract Manufacturing & Services
Enzene Inc.
Exhibitor at CPHI Milan 2026
About Us
Categories
-
Country/Region:United States
-
On CPHI since:2024
-
Certificates:3
-
Employees:500 - 999
Company types
Primary activities
Contact info
-
-
37 Easton Avenue, Suite 200, 08901, New Brunswick, New Jersey, United States
Event information
CPHI Milan 2026
-
6 Oct 2026 - 8 Oct 2026
-
Fiera Milano, Italy
-
Visit us at stand 12C57, Contract Manufacturing & Services
Products Featured at CPHI Milan 2026
-
Product Denosumab Biosimilars
Biosimilar to Xgeva and Prolia, launched in India in 2021 with a scheduled biosimilar launch in 2026, globally. -
Product Romiplostim Biosimilar
Biosimilar to Nplate, launched in India in 2021. -
Product Teriparatide Biosimilar
Biosimilar to Forteo/Forsteo , Successful launch in 2021 •Proven safety and efficacy: ~300k doses delivered •Market-leading product •Cost competitive
•EU filed with Phase 1 clinical •Fully vetted product development strategy with EMA and USFDA
...
Enzene Inc. Resources (1)
-
.png)
Video Breaking the $40 per Gram Barrier for Mabs With Fully-Connected Continuous Manufacturing (Fccm)
Traditional biologics manufacturing relies on batch processing, which involves sequential operations and faces significant limitations, such as low productivity, lengthy processing times, and high operational costs due to large infrastructure needs and frequent manual interventions. To overcome these challenges, Enzene has introduced a commercially validated, fully-connected continuous manufacturing platform (FCCM) for protein-based therapeutics. This platform, EnzeneX™, operates continuously from upstream to downstream, enhancing productivity with a smaller facility footprint. It achieves higher cell densities and viabilities, resulting in up to ten times greater productivity than traditional methods. EnzeneX™ 2.0 aims to reduce mAb production costs to less than $40 per gram, making life-saving medicines more affordable and accessible globally.